MaxCyte Latest News

MaxCyte is thrilled to have joined forces with Ori Biotech, to help improve the scalability, efficiency, and accessibility of gene-edited cell therapies! By integrating our ExPERT Electroporation platform with Ori’s IRO manufacturing system, our collaboration aims to: improve gene-edited T cell yield, shorten manufacturing timelines, support a seamless path from R&D to GMP production. Read more.

When research funding is limited, every decision matters. In this issue, read how MaxCyte is reducing inefficiencies in gene and cell therapy as well as assay development. Find on-demand and upcoming resources to help save time and funding in your work.

From his recent presentation during Technology Networks’ Cell and Gene Therapy 2025 Symposium, MaxCyte’s Dr. Andrew Guy Mancini explores the rapid evolution of engineered cell therapies, and what’s next for the field. From the rise of non-viral delivery methods to the shift toward allogeneic approaches, Dr. Mancini highlights how developers are tackling complexity, scalability, and cost to bring next-generation therapies to more patients.

From advances in cell therapy to changes at MaxCyte®, the past few months have been busy. Through it all, we remain committed to helping you solve the toughest cell engineering challenges with our proven ExPERT™ platform and trusted support. This issue of MaxCyte Minutes Newsletter has a lot in store! Let’s dive in. Read more. . . .

TG Therapeutics to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases

This strategic acquisition strengthens MaxCyte’s ability to serve ex vivo and in vivo cell and gene therapy (CGT) developers with an innovative suite of tools and services spanning early R&D through clinical development and commercialization. By integrating SeQure Dx into MaxCyte, Maxcyte will expand its service offerings and leverage its commercial and field application scientist teams to work with developers earlier in their research processes. SeQure Dx is revenue generating and expected to be accretive to MaxCyte’s revenue growth.

In the last three months, new collaboration between the University of California San Diego Sanford Stem Cell Institute (SSCI) and MaxCyte, Webinar on Next-Generation genetic discovery systems in human immune cells, Scientific poster on High efficiency complex gene editing of hard-to-transfect primary cells using MaxCyte electroporation in combination with Synthego sgRNAs.

Jeremy Kolenbrander is Senior VP of Product Development and Engineering at MaxCyte, he was drawn to cell and gene therapy as it has the ability to make a huge difference in the lives of patients and their caregivers. He joined MaxCyte in early in 2024.

MaxCyte marks over a quarter-century remaining steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.

New collaboration aims to improve patient outcomes and boost biopharma workforce development.